REVELATION BIOSCIENCES INC
For the period ended Sep 30, 2024. Filed Nov 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 8, 2024
REVB$3.94-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months EndedSeptember 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(13,312,817) | 2,082,649 |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | ||
| Stock-based compensation expense | 96,284 | 123,626 |
| Issuance of common stock for services | 25,000 | — |
| Depreciation expense | 20,702 | 18,787 |
| Change in fair value of warrant liability | (78,884) | (8,260,735) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (33,155) | (79,505) |
| Deferred offering costs | 71,133 | 61,154 |
| Accounts payable | 1,767,450 | 720,936 |
| Accrued expenses | (3,129,348) | 49,638 |
| Net cash used in operating activities | (14,573,635) | (5,283,450) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (36,860) | — |
| Net cash used in investing activities | (36,860) | — |
| Cash flows from financing activities: | ||
| Proceeds from the February 2024 Public Offering, net | 5,417,053 | — |
| Proceeds from the Class D Common Stock Warrants exercises | 241,390 | — |
| Proceeds from the Warrant Inducement exercises, net | 3,501,276 | — |
| Proceeds from Class D Pre-Funded Warrants exercise | 127 | — |
| Redemption of Series A Preferred Stock | — | (5,000) |
| Proceeds from the February 2023 Public Offering, net | — | 14,029,974 |
| Proceeds from Class C Pre-Funded Warrants exercise | — | 34 |
| Net cash provided by financing activities | 9,159,846 | 14,025,008 |
| Net (decrease) increase in cash and cash equivalents | (5,450,649) | 8,741,558 |
| Cash and cash equivalents at beginning of period | 11,991,701 | 5,252,979 |
| Cash and cash equivalents at end of period | $6,541,052 | $13,994,537 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Fair Value of Class E Common Stock Warrants in connection with the Warrant Inducement | $4,887,683 | $— |
| Incremental fair value of the Class D Common Stock Warrants in connection with the Warrant Inducement | $337,131 | $— |
| Equity issuance costs in connection with the Warrant Inducement included in accounts payable | $25,968 | $— |
| Fair Value of Class D Common Stock Warrants in connection with the February 2024 Public Offering | $6,269,684 | $— |
| Fair Value of Class C Common Stock Warrants in connection with the February 2023 Public Offering | $— | $13,996,500 |
| Alternative cashless exercise of Class C Common Stock Warrants | $57,589 | $5,526,287 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.